Price
$47.96
Increased by +0.52%
Dollar Volume
26.06 M
ADR%
5.21
Earnings Report Date (estimate)
Feb 23, 23 (-0.8)
Market Cap.
2.24 B
Shares Float
31.73 M
Shares Outstanding
46.76 M
Beta
-0.91
Price / Earnings
-14.98
BPR
918.12
20D Range
42.64 52.67
50D Range
35.80 54.88
200D Range
7.52 54.88
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 4, 22 -0.92
Decreased by -31.43%
-0.74
Decreased by -24.32%
Aug 4, 22 -0.77
Increased by +7.23%
-0.86
Increased by +10.47%
May 6, 22 -0.74
Decreased by -72.09%
-0.80
Increased by +7.50%
Feb 25, 22 -0.93
Decreased by -8.14%
-0.82
Decreased by -13.41%
Nov 12, 21 -0.70
Decreased by -11.11%
-0.91
Increased by +23.08%
Aug 13, 21 -0.83
Decreased by -45.61%
-0.72
Decreased by -15.28%
May 13, 21 -0.43
Decreased by -2.38%
-0.91
Increased by +52.75%
Mar 16, 21 -0.86
Decreased by -56.36%
-0.59
Decreased by -45.76%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-35.54 M
Decreased by -46.08%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-27.40 M
Increased by +5.29%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-26.03 M
Decreased by -72.49%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-32.42 M
Decreased by -9.13%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-24.33 M
Decreased by -13.68%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-28.93 M
Decreased by -78.52%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-15.09 M
Decreased by -26.96%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-29.71 M
Decreased by -90.32%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.